The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
Break Apart Probe
- Order Number
- Package Size
- 100 µl
Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category AML with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features when 20% or more blood or marrow blasts are present.
The inv(16) and related t(16;16) are found in 10 % of all cases with de novo AML. In these rearrangements the core binding factor b (CBFB) gene on 16q22 is fused to the smooth muscle myosin heavy chain gene (MYH11) on 16p13. This cytogenetic group is usually associated with high complete remission rates and a relatively favorable outcome, especially when treated with repetitive cycles of highdose cytarabine as consolidation therapy.
- Acute Myelogenous Leukemia (AML)
Two green-orange colocalization/fusion signals (2GO).
Aberrant Cell (typical results):
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the relevant locus.
- Doehner et al (2010) Blood 115: 453-474
- Froehling et al (2002) J Clin Oncol 20:2480-2485
- Arber et al (2016) Blood 127:2391-2405